



INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

10/022,609.171USC5

Application Number:

10/022,609

Applicant: VANDLEN ET AL.

Filing Date: DECEMBER 17, 2001

Group Art Unit: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

no pages listed	Maniatis et al., "Molecular Cloning: A Laboratory Manual", 1st edition, New York Cold Spring Harbor Lab Press, Chapter 12, pps. Selected pages (1982)
PCV	Nosoh et al., "Protein Stability and Stabilization through Protein Engineering", New York, New York: Ellis Horwood Ltd., pp. 26, 27, 55-56, 62, 143, 180 (1991).
inappropriate not published	Paper No. 7 dated March 20, 1995 from the history of Serial No. 08/096,277, now U.S. Patent No. 5,875,482, authored by Lawrence H. Posorske, publicly available as of the issue date of the patent of November 26, 1996.
inappropriate not published	Paper No. 8 dated June 29, 1995 from file history of Serial No. 08/096,277, now U.S. Patent No. 5,875,482, authored by U.S. PTO Examiner, publicly available as of issue date of the patent of November 26, 1996.

23552

PATENT TRADEMARK OFFICE

EXAMINER

P. L. L. L.

DATE CONSIDERED

3/31/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0712C5Serial No. 10/022609
To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Vandlen et al.Filing Date
17 Dec 2001Group
To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
RCH	* 1	4,683,195	28.07.87	Mullis et al.			
	* 2	4,882,275	21.11.89	Klagsburn			07.04.86
	* 3	4,968,603	06.11.90	Slamon et al.			
	* 4	5,169,837	08.12.92	Lagarde et al.			28.03.91
	* 5	5,237,056	17.08.93	Fischbach			
	* 6	5,367,060	22.11.94	Vandlen et al.			
	* 7	5,464,751	07.11.95	Greene et al.			
	* 8	5,578,482	26.11.96	Lippman et al.			
	* 9	5,594,114	14.01.97	Goodearl et al.			23.09.94
	* 10	5,641,869	24.06.97	Vandlen et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
RCH	* 11	505,148	23.09.92	EPO				
	* 12	WO 91/15230	17.10.91	PCT WIPO				
	* 13	WO 91/18921	12.12.91	PCT				
	* 14	WO 92/00595	03.04.92	PCT				
	* 15	WO 92/12174	23.07.92	PCT				
	* 16	WO 92/18627	29.10.92	PCT				
	* 17	WO 93/22339	11.11.93	PCT				
	* 18	WO 93/22424	11.11.93	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RCH	* 19	Bargmann et al., "Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185" <u>Cell</u> 45:649-657 (June 6, 1986)
	* 20	Benveniste et al., "Purification and characterization of a human T-lymphocyte-derived glial growth-promoting factor" <u>Proc. Natl. Acad. Sci.</u> 82:3930-3934 (1985)
	* 21	Brookes et al., "Glial growth factor-like activity in Schwann Cell tumors" <u>Annals of Neurology</u> 20:317-322 (1986)
	* 22	Brookes et al., "Purification and preliminary characterization of a glial growth factor from the bovine pituitary" <u>Journal of Biological Chemistry</u> 255(18):8374-8377 (1980)
	* 23	Brookes, "Assay and isolation of glial growth factor from the bovine pituitary" <u>Methods in Enzymology</u> 147:217-225 (1987)
	* 24	Cohen, J.A. et al., "Expression of the neu proto-oncogene by Schwann Cells during peripheral nerve development and Wallerian degeneration" <u>J. Neuroscience Res.</u> 31:622-634 (1992)
	* 25	Davis et al., "Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium" <u>Biochem. & Biophys. Res. Comm.</u> 179(3):1536-1542 (1991)
	* 26	Davis et al., "Platelet-derived growth factors and fibroblast growth factors are mitogens for rat Schwann Cells" <u>Journal of Cell Biology</u> 110:1353-1360 (1990)

Examiner

RCH

Date Considered

3/31/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0712C5	Serial No. <u>10/022649</u> To Be Assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Vandien et al.	
				Filing Date 17 Dec 2001	Group <u>1647</u> To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
RCV	*27	De Corte et al., "A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells" <u>J. Cell Science</u> 107:405-416 (1994)			
	*28	Dobashi et al., "Characterization of a neu/c-erbB-2 protein-specific activating factor" <u>Proc. Natl. Acad. Sci.</u> 88:8582-8596 (1991)			
	*29	Falls et al., "ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family" <u>Cell</u> 72:801-815 (1993)			
	*30	Fitzgerald et al., "Characterization and Sequence Analysis of the Human Ornithine Decarboxylase Gene" <u>DNA</u> 8(9):623-634 (1989)			
	*31	Gray et al., "Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor" <u>Nature</u> 303:722-725 (1983)			
	*32	Groenen et al., "Structure-Function Relationships for the EGF/TGF- α Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)			
	*33	Hoffman, Michelle, "New Clue Found to Oncogene's Role in Breast Cancer" <u>Science</u> 256:1129 (1992)			
	*34	Holmes et al., "Identification of Heregulin, A Specific Activator of p185 ^{erbB2} " <u>Science</u> 256:1205-1210 (May 22, 1992)			
	*35	Hudziak et al., "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)			
	*36	Kimura et al., "Structure, expression and function of a schwannoma-derived growth factor" <u>Nature</u> 348:257-260 (1990)			
	*37	Kokai et al., "Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products" <u>Proc. Natl. Acad. Sci. USA</u> 85:5389-5393 (1988)			
	*38	Kunisada et al., "Sequence Organization of Repetitive Sequences Enriched in Small Polydisperse Circular DNAs from HeLa Cells" <u>J. Mol. Biol.</u> 198:557-565 (1987)			
	*39	Lemke & Brookes, "Identification and purification of glial growth factor" <u>J. Neurosci.</u> 4(1):75-83 (1984)			
	*40	Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185 ^{erbB2} " <u>Science</u> 249:1552-1555 (1990)			
	*41	Lupu et al., "Purification and Characterization of a Novel Growth Factor from Human Breast Cancer Cells" <u>Biochemistry</u> 31:7330-7340 (1992)			
	*42	Lupu et al., "Purification of a novel growth factor that binds exclusively to the erbB-2 receptor protein and induces cellular responses" <u>Proc. Am. Assoc. Cancer Res.</u> 32:abst. no. 297, p. 50 (1991)			
no cited pages	*43	Maniatis et al., Molecular Cloning, A Laboratory Manual, 1st edition, New York: Cold Spring Harbor Lab. Press, Chapter 12, pps. selected pages (1982).			
RCV	*44	Marchionni et al., "Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system" <u>Nature</u> 362:312-318 (1993)			
	*45	Nagata et al., "Solution structure of the epidermal growth factor-like domain of heregulin- α , a ligand for p180 ^{erbB-4} " <u>EMBO J.</u> 13(15):3517-3523 (1994)			
duplicate citation	*46	Noosh et al., Protein Stability and Stabilization through Protein Engineering, New York: Ellis Harwood, pps. 25, 27, 55, 56, 62, 143, 180, (1991).			
Examiner P. I. Kaya				Date Considered 3/3/04	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

